1
|
Romero R, Sánchez-Rivera FJ, Westcott PMK, Mercer KL, Bhutkar A, Muir A, González Robles TJ, Rodríguez SL, Liao LZ, Ng SR, Li L, Colón CI, Naranjo S, Beytagh MC, Lewis CA, Hsu PP, Bronson RT, Vander Heiden MG, Jacks T. Publisher Correction: Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. Nat Cancer 2020; 1:935. [PMID: 35121957 DOI: 10.1038/s43018-020-00118-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- Rodrigo Romero
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
| | - Francisco J Sánchez-Rivera
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
- Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - Kim L Mercer
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Howard Hughes Medical Institute, Chevy Chase, MD, USA
| | - Arjun Bhutkar
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
| | - Alexander Muir
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Ben May Department for Cancer Research, University of Chicago, Chicago, IL, USA
| | | | | | - Laura Z Liao
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
| | - Sheng Rong Ng
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
| | - Leanne Li
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
| | - Caterina I Colón
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
| | - Santiago Naranjo
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
| | - Mary Clare Beytagh
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
| | - Caroline A Lewis
- Whitehead Institute, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Peggy P Hsu
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts General Hospital Cancer Center, Boston, MA, USA
- Dana-Farber Cancer Institute, Boston, MA, USA
| | - Roderick T Bronson
- Tufts University, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Matthew G Vander Heiden
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
- Dana-Farber Cancer Institute, Boston, MA, USA
| | - Tyler Jacks
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA.
- Howard Hughes Medical Institute, Chevy Chase, MD, USA.
| |
Collapse
|
2
|
Romero R, Sánchez-Rivera FJ, Westcott PMK, Mercer KL, Bhutkar A, Muir A, González Robles TJ, Lamboy Rodríguez S, Liao LZ, Ng SR, Li L, Colón CI, Naranjo S, Beytagh MC, Lewis CA, Hsu PP, Bronson RT, Vander Heiden MG, Jacks T. Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. Nat Cancer 2020; 1:589-602. [PMID: 34414377 PMCID: PMC8373048 DOI: 10.1038/s43018-020-0071-1] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Accepted: 05/01/2020] [Indexed: 12/13/2022]
Abstract
Approximately 20-30% of human lung adenocarcinomas (LUAD) harbor loss-of-function (LOF) mutations in Kelch-like ECH Associated-Protein 1 (KEAP1), which lead to hyperactivation of the nuclear factor, erythroid 2-like 2 (NRF2) antioxidant pathway and correlate with poor prognosis1-3. We previously showed that Keap1 mutation accelerates KRAS-driven LUAD and produces a marked dependency on glutaminolysis4. To extend the investigation of genetic dependencies in the context of Keap1 mutation, we performed a druggable genome CRISPR-Cas9 screen in Keap1-mutant cells. This analysis uncovered a profound Keap1 mutant-specific dependency on solute carrier family 33 member 1 (Slc33a1), an endomembrane-associated protein with roles in autophagy regulation5, as well as a series of functionally-related genes implicated in the unfolded protein response. Targeted genetic and biochemical experiments using mouse and human Keap1-mutant tumor lines, as well as preclinical genetically-engineered mouse models (GEMMs) of LUAD, validate Slc33a1 as a robust Keap1-mutant-specific dependency. Furthermore, unbiased genome-wide CRISPR screening identified additional genes related to Slc33a1 dependency. Overall, our study provides a strong rationale for stratification of patients harboring KEAP1-mutant or NRF2-hyperactivated tumors as likely responders to targeted SLC33A1 inhibition and underscores the value of integrating functional genetic approaches with GEMMs to identify and validate genotype-specific therapeutic targets.
Collapse
Affiliation(s)
- Rodrigo Romero
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
| | - Francisco J Sánchez-Rivera
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
- Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - Kim L Mercer
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Howard Hughes Medical Institute, Chevy Chase, MD, USA
| | - Arjun Bhutkar
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
| | - Alexander Muir
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Ben May Department for Cancer Research, University of Chicago, Chicago, IL, USA
| | | | | | - Laura Z Liao
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
| | - Sheng Rong Ng
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
| | - Leanne Li
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
| | - Caterina I Colón
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
| | - Santiago Naranjo
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
| | - Mary Clare Beytagh
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
| | - Caroline A Lewis
- Whitehead Institute, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Peggy P Hsu
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts General Hospital Cancer Center, Boston, MA, USA
- Dana-Farber Cancer Institute, Boston, MA, USA
| | - Roderick T Bronson
- Tufts University, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Matthew G Vander Heiden
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA
- Dana-Farber Cancer Institute, Boston, MA, USA
| | - Tyler Jacks
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
- Massachusetts Institute of Technology Department of Biology, Cambridge, MA, USA.
- Howard Hughes Medical Institute, Chevy Chase, MD, USA.
| |
Collapse
|